Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | SNCA | P37840 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225916 | 0.90 | MAPT (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL29640485 | 0.90 | MAPT (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL29321272 | 0.89 | NOX1 (0.52) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL225829 | 0.89 | NOX1 (0.65) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL2756476 | 0.86 | NOX1 (0.53) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL11381973 | 0.83 | MAOA (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL14140472 | 0.82 | NOX1 (0.55) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL6315328 | 0.81 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL9114 | 0.81 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL2504207 | 0.81 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | claimed |
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-10-19 | — | — | US | claimed |
| EP-4260861-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | Seoul National University R & DB Foundation (KR) | 2023-10-18 | — | — | EP | claimed |
| EP-0122989-B1 | STABILIZED POLYOXYALKYLENE POLYETHER POLYOLS AND POLYURETHANE FOAMS PREPARED THEREFROM | ATLANTIC RICHFIELD COMPANY (US) | 1987-05-13 | — | — | EP | claimed |
| EP-0122989-A1 | Stabilized polyoxyalkylene polyether polyols and polyurethane foams prepared therefrom | ATLANTIC RICHFIELD COMPANY (US) | 1984-10-31 | — | — | EP | claimed |
| US-4444676-A | Stabilized polyoxyalkylene polyether polyols and polyurethane foams prepared therefrom | ATLANTIC RICHFIELD COMPANY (US) | 1984-04-24 | — | — | US | claimed |
| JP-7138243-A | — | — | None | — | — | JP | disclosed |
| US-20250376556-A1 | Curable Epoxy Resin Compositions with High Glass Transition Tempature | HUNTSMAN ADVANCED MAT AMERICAS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | disclosed |
| EP-4547728-A2 | CURABLE EPOXY RESIN COMPOSITIONS WITH HIGH GLASS TRANSITION TEMPERATURE | Huntsman Advanced Materials Americas LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119487097-A | Curable epoxy resin composition with high glass transition temperature | 亨斯迈先进材料美国有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024006101-A2 | CURABLE EPOXY RESIN COMPOSITIONS WITH HIGH GLASS TRANSITION TEMPERATURE | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-10-19 | — | — | US | disclosed |
| EP-0517656-B1 | Fire-protected polyimide composition | CIBA GEIGY AG (CH) | 1997-08-20 | — | — | EP | disclosed |
| US-5637387-A | PREPOLYMER OF BISMALEIMIDE AND ALKENYLPHENOL STABILIZED WITH PHENOTHIAZINE OR DERIVATIVE THEREOF OR HYDROQUINONE | CIBA-GEIGY CORPORATION (US) | 1997-06-10 | — | — | US | disclosed |
| JP-H07138243-A | PRODUCTION OF PHENOTHIAZINES | KAWAGUCHI KAGAKU KOGYO KK | 1995-05-30 | — | — | JP | disclosed |
| US-5240981-A | Blend with alkenylphenol, tribromophenylmaleimide, free radical catalyst, and phenothiazine derivative | CIBA-GEIGY CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-5221764-A | During elevated temperature shipping or during storage; adding a cerium compound and a phenylenediamine compound | BETZ LABORATORIES, INC. (US) | 1993-06-22 | — | — | US | disclosed |
| EP-0517656-A2 | Fire-protected polyimide composition | CIBA-GEIGY AG (CH) | 1992-12-09 | — | — | EP | disclosed |
| EP-0122989-B1 | STABILIZED POLYOXYALKYLENE POLYETHER POLYOLS AND POLYURETHANE FOAMS PREPARED THEREFROM | ATLANTIC RICHFIELD COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP50, NUP188 | NOX1 3666/4885MAPT 2789/4885GAA 2995/4885 |
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP188, NUP50 | NOX1 3568/4885MAPT 2909/4885GAA 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.